Zolmitriptan for migraine

What zolmitriptan is

Zolmitriptan is a serotonin (5-HT1B/1D) receptor agonist, or triptan. US labels indicate it for acute treatment of migraine with or without aura, after a clear diagnosis. It is not indicated for preventing attacks, and the labels state that safety and effectiveness in cluster headache have not been established. Approval and forms differ by country.

Three forms

Form	US label age	Peak blood level
Tablets (Zomig)	Adults; not recommended under 18	Median 1.5 hours
Orally disintegrating tablets (Zomig-ZMT, generics)	Adults; not recommended under 18	Median 3 hours
Nasal spray	Adults and from age 12	Detected by 5 minutes; peak generally by 3 hours

The 2024 Zomig label covers tablets only. Details of the orally disintegrating tablet come from the 2019 Zomig and Zomig-ZMT label. The orally disintegrating tablet dissolves on the tongue and needs no liquid. It contains phenylalanine, which can be harmful to people with phenylketonuria. Doses differ by form and come from the label or the prescriber.

Results at 2 hours

Headache response means moderate or severe pain reduced to mild or none.

Form	Population	Zolmitriptan	Placebo
Tablets, 5 trials	Adults	27–67%	16–44%
Orally disintegrating tablet, 1 trial	Adults	63%	22%
Nasal spray, 1 trial	Adults	55–69%	31%
Nasal spray, 1 trial	Ages 12 to 17	51–53%	39%

Ranges cover the doses tested. The 27% is the lowest dose in the smallest trial, the only arm not significantly better than placebo. In the teenage trial, no pain at 2 hours was reached by 25% and 30% on the two doses against 17% on placebo, and only the higher dose was significant.

A Cochrane review (Bird 2014, 25 studies, 20,162 participants) reports for one tablet dose: pain freedom at 2 hours 30% against 10% with placebo, headache relief 61% against 29%. With another dose, only 14% were pain-free at 2 hours with no return of pain within 24 hours.

Contraindications and warnings

The Zomig label says zolmitriptan must not be used with:

• ischemic coronary artery disease, other significant cardiovascular disease, or coronary vasospasm;
• Wolff-Parkinson-White syndrome or similar arrhythmias;
• a history of stroke, transient ischemic attack, or hemiplegic or basilar migraine;
• peripheral vascular disease, ischemic bowel disease, or uncontrolled hypertension;
• another 5-HT1 agonist or ergot-type medicine within 24 hours;
• an MAO-A inhibitor now or within 2 weeks;
• hypersensitivity to zolmitriptan.

Liver. Blood levels rose in moderate to severe liver impairment, with significant blood pressure rises in some patients. The tablet label adjusts the dose for these patients, and the nasal spray is not recommended for them.

Cimetidine. Cimetidine about doubled the half-life and blood levels of zolmitriptan, and the labels limit the dose for people taking it.

SSRIs and SNRIs. The tablet label reports life-threatening serotonin syndrome when triptans were combined with SSRIs or SNRIs.

Nasal spray. Unusual taste was reported by 17% to 21% of adults against 3% on placebo.

Other label warnings cover heart attack, arrhythmia, chest or jaw tightness, stroke, reduced blood flow to the bowel or limbs, and raised blood pressure.

Monthly limit

ICHD-3 counts a triptan in any formulation, with a limit of 10 or more days a month for more than 3 months. The Zomig label warns about medication-overuse headache at 10 or more days a month. See the medication days counter.

In a headache diary

Record the form and the pain at 2 hours. Add a note at 24 hours if pain came back, because the 14% figure above combines both outcomes and a 2-hour entry alone does not show it.